A nurse is monitoring a client who is receiving diazepam for moderate sedation. The nurse should monitor the client for which of the following adverse effects?

Simvastatin is an HMG-CoA reductase inhibitorused to treat dyslipidemia by reducing hepatic cholesterol synthesis. While effective for cardiovascular prophylaxis, it carries risks of hepatotoxicityand myopathy. Clinical monitoring focuses on liver function tests and markers of muscle integrity to detect early signs of statin-inducedorgan injury.

Rationale:

A.Decreased creatine kinase (CK) is not a finding of clinical concern; however, increased CK would be highly significant. Elevated CK levels indicate muscle breakdown or rhabdomyolysis, which is a rare but severe side effect of statin therapy. A low or normal CK level suggests that the medication is not currently causing significant damage to the client's skeletal muscle tissue.

B.Increased alkaline phosphatase is a marker of potential liver injury or biliary obstruction and must be reported to the provider immediately. Since simvastatin is processed by the liver, it can cause asymptomatic elevations in liver enzymes or, in rare cases, drug-induced hepatitis. The nurse must monitor for jaundice and upper quadrant pain when these laboratory values are elevated.

C.Increased HDL is a positive therapeutic outcome of simvastatin therapy and does not need to be reported as an adverse finding. High-density lipoprotein is the "good" cholesterol that aids in the transport of cholesterol away from the arteries. An increase in this value indicates that the medication and lifestyle changes are successfully reducing the client's overall cardiovascular risk profile.

D.Decreased HbA1c is generally a favorable finding, as it indicates improved long-term glucose control. Statins have actually been associated with a slight increase in HbA1c and blood glucose levels in some patients, potentially increasing the risk of diabetes. Therefore, a decrease would not be considered a medication-related adverse effect that requires urgent notification to the healthcare provider.

Methimazole is an antithyroidagent that inhibits the enzyme thyroid peroxidase, preventing the iodination of tyrosine and the synthesis of T3 and T4. It is used to manage hyperthyroidismby shifting the patient from a hypermetabolic state back toward a euthyroid physiological balance.

Rationale:

A.Weight loss is a clinical manifestation of the hyperthyroidism seen in Graves' disease, not an expected therapeutic effect of methimazole. As the medication successfully lowers thyroid hormone levels, the client's basal metabolic rate slows down, typically resulting in weight gain or stabilization. The nurse should expect the client to stop losing weight as the treatment becomes effective.

B.An increase in pulse rate is a symptom of untreated hyperthyroidism due to the stimulatory effects of excess thyroid hormones on the cardiovascular system. Methimazole therapy should result in a decrease in heart rate as the metabolic demand lessens. If the pulse remains high, it may indicate that the dosage is not yet sufficient to control the disease.

C.Increased sleeping is an expected therapeutic outcome because methimazole reduces the hypermetabolic state that causes insomnia and restlessness in Graves' disease. As thyroid hormone levels normalize, the client's central nervous system activity decreases, allowing for more restorative rest. This shift indicates that the medication is successfully reversing the thyrotoxicosis and bringing the patient toward a euthyroid state.

D.Warmer skin and heat intolerance are classic signs of hyperthyroidism caused by increased thermogenesis. Methimazole works to lower the body's metabolic rate, which should result in cooler skin and an improved tolerance to ambient temperatures. If the skin remains excessively warm and moist, the client may still be in a hyperthyroid state requiring further titration of the medication.